Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
CAMP4 Therapeutics partners with Alnylam on finding new liver disease drug targets
by Ryan Cross
January 27, 2019
| A version of this story appeared in
Volume 97, Issue 4
Alnylam Pharmaceuticals, a developer of RNA interference (RNAi) therapies, is partnering with CAMP4 Therapeutics to find new drug targets for a rare liver disease. CAMP4, which announced raising $30 million in series A financing in May 2018, uses computational tools to understand the rules dictating how genes are regulated—turned up or down—in cell types across the body. Because Alnylam’s RNAi drugs work by effectively turning genes down, the partnership may provide the first big test of CAMP4’s technology.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X